Cargando…
Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
The introduction of novel therapeutic agents for advanced prostate cancer has led to a wide range of treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). In the past decade, new treatment options for mCRPC, including abiraterone, enzalutamide, docetaxel, cabaz...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Society for Sexual Medicine and Andrology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523115/ https://www.ncbi.nlm.nih.gov/pubmed/36792090 http://dx.doi.org/10.5534/wjmh.220200 |